Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain

Philipp A. Jaeger, Kurt M. Lucin, Markus Britschgi, Badri Vardarajan, Ruo Pan Huang, Elizabeth D. Kirby, Rachelle Abbey, Bradley F Boeve, Adam L. Boxer, Lindsay A. Farrer, Nicole Finch, Neill R Graff Radford, Elizabeth Head, Matan Hofree, Ruochun Huang, Hudson Johns, Anna Karydas, David S Knopman, Andrey Loboda, Eliezer MasliahRamya Narasimhan, Ronald Carl Petersen, Alexei Podtelezhnikov, Suraj Pradhan, Rosa V Rademakers, Chung Huan Sun, Steven G Younkin, Bruce L. Miller, Trey Ideker, Tony Wyss-Coray

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Biological pathways that significantly contribute to sporadic Alzheimer's disease are largely unknown and cannot be observed directly. Cognitive symptoms appear only decades after the molecular disease onset, further complicating analyses. As a consequence, molecular research is often restricted to late-stage post-mortem studies of brain tissue. However, the disease process is expected to trigger numerous cellular signaling pathways and modulate the local and systemic environment, and resulting changes in secreted signaling molecules carry information about otherwise inaccessible pathological processes. Results: To access this information we probed relative levels of close to 600 secreted signaling proteins from patients' blood samples using antibody microarrays and mapped disease-specific molecular networks. Using these networks as seeds we then employed independent genome and transcriptome data sets to corroborate potential pathogenic pathways. Conclusions: We identified Growth-Differentiation Factor (GDF) signaling as a novel Alzheimer's disease-relevant pathway supported by in vivo and in vitro follow-up experiments, demonstrating the existence of a highly informative link between cellular pathology and changes in circulatory signaling proteins.

Original languageEnglish (US)
Article number31
JournalMolecular Neurodegeneration
Volume11
Issue number1
DOIs
StatePublished - Apr 26 2016

Fingerprint

Proteomics
Alzheimer Disease
Brain
Growth Differentiation Factors
Access to Information
Neurobehavioral Manifestations
Pathologic Processes
Transcriptome
Blood Proteins
Seeds
Genome
Pathology
Antibodies
Research
Proteins
Datasets
In Vitro Techniques

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Clinical Neurology
  • Molecular Biology

Cite this

Jaeger, P. A., Lucin, K. M., Britschgi, M., Vardarajan, B., Huang, R. P., Kirby, E. D., ... Wyss-Coray, T. (2016). Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Molecular Neurodegeneration, 11(1), [31]. https://doi.org/10.1186/s13024-016-0095-2

Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. / Jaeger, Philipp A.; Lucin, Kurt M.; Britschgi, Markus; Vardarajan, Badri; Huang, Ruo Pan; Kirby, Elizabeth D.; Abbey, Rachelle; Boeve, Bradley F; Boxer, Adam L.; Farrer, Lindsay A.; Finch, Nicole; Graff Radford, Neill R; Head, Elizabeth; Hofree, Matan; Huang, Ruochun; Johns, Hudson; Karydas, Anna; Knopman, David S; Loboda, Andrey; Masliah, Eliezer; Narasimhan, Ramya; Petersen, Ronald Carl; Podtelezhnikov, Alexei; Pradhan, Suraj; Rademakers, Rosa V; Sun, Chung Huan; Younkin, Steven G; Miller, Bruce L.; Ideker, Trey; Wyss-Coray, Tony.

In: Molecular Neurodegeneration, Vol. 11, No. 1, 31, 26.04.2016.

Research output: Contribution to journalArticle

Jaeger, PA, Lucin, KM, Britschgi, M, Vardarajan, B, Huang, RP, Kirby, ED, Abbey, R, Boeve, BF, Boxer, AL, Farrer, LA, Finch, N, Graff Radford, NR, Head, E, Hofree, M, Huang, R, Johns, H, Karydas, A, Knopman, DS, Loboda, A, Masliah, E, Narasimhan, R, Petersen, RC, Podtelezhnikov, A, Pradhan, S, Rademakers, RV, Sun, CH, Younkin, SG, Miller, BL, Ideker, T & Wyss-Coray, T 2016, 'Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain', Molecular Neurodegeneration, vol. 11, no. 1, 31. https://doi.org/10.1186/s13024-016-0095-2
Jaeger PA, Lucin KM, Britschgi M, Vardarajan B, Huang RP, Kirby ED et al. Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Molecular Neurodegeneration. 2016 Apr 26;11(1). 31. https://doi.org/10.1186/s13024-016-0095-2
Jaeger, Philipp A. ; Lucin, Kurt M. ; Britschgi, Markus ; Vardarajan, Badri ; Huang, Ruo Pan ; Kirby, Elizabeth D. ; Abbey, Rachelle ; Boeve, Bradley F ; Boxer, Adam L. ; Farrer, Lindsay A. ; Finch, Nicole ; Graff Radford, Neill R ; Head, Elizabeth ; Hofree, Matan ; Huang, Ruochun ; Johns, Hudson ; Karydas, Anna ; Knopman, David S ; Loboda, Andrey ; Masliah, Eliezer ; Narasimhan, Ramya ; Petersen, Ronald Carl ; Podtelezhnikov, Alexei ; Pradhan, Suraj ; Rademakers, Rosa V ; Sun, Chung Huan ; Younkin, Steven G ; Miller, Bruce L. ; Ideker, Trey ; Wyss-Coray, Tony. / Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. In: Molecular Neurodegeneration. 2016 ; Vol. 11, No. 1.
@article{6b5d8f0608ff4761b2d5665523ea41e0,
title = "Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain",
abstract = "Background: Biological pathways that significantly contribute to sporadic Alzheimer's disease are largely unknown and cannot be observed directly. Cognitive symptoms appear only decades after the molecular disease onset, further complicating analyses. As a consequence, molecular research is often restricted to late-stage post-mortem studies of brain tissue. However, the disease process is expected to trigger numerous cellular signaling pathways and modulate the local and systemic environment, and resulting changes in secreted signaling molecules carry information about otherwise inaccessible pathological processes. Results: To access this information we probed relative levels of close to 600 secreted signaling proteins from patients' blood samples using antibody microarrays and mapped disease-specific molecular networks. Using these networks as seeds we then employed independent genome and transcriptome data sets to corroborate potential pathogenic pathways. Conclusions: We identified Growth-Differentiation Factor (GDF) signaling as a novel Alzheimer's disease-relevant pathway supported by in vivo and in vitro follow-up experiments, demonstrating the existence of a highly informative link between cellular pathology and changes in circulatory signaling proteins.",
author = "Jaeger, {Philipp A.} and Lucin, {Kurt M.} and Markus Britschgi and Badri Vardarajan and Huang, {Ruo Pan} and Kirby, {Elizabeth D.} and Rachelle Abbey and Boeve, {Bradley F} and Boxer, {Adam L.} and Farrer, {Lindsay A.} and Nicole Finch and {Graff Radford}, {Neill R} and Elizabeth Head and Matan Hofree and Ruochun Huang and Hudson Johns and Anna Karydas and Knopman, {David S} and Andrey Loboda and Eliezer Masliah and Ramya Narasimhan and Petersen, {Ronald Carl} and Alexei Podtelezhnikov and Suraj Pradhan and Rademakers, {Rosa V} and Sun, {Chung Huan} and Younkin, {Steven G} and Miller, {Bruce L.} and Trey Ideker and Tony Wyss-Coray",
year = "2016",
month = "4",
day = "26",
doi = "10.1186/s13024-016-0095-2",
language = "English (US)",
volume = "11",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain

AU - Jaeger, Philipp A.

AU - Lucin, Kurt M.

AU - Britschgi, Markus

AU - Vardarajan, Badri

AU - Huang, Ruo Pan

AU - Kirby, Elizabeth D.

AU - Abbey, Rachelle

AU - Boeve, Bradley F

AU - Boxer, Adam L.

AU - Farrer, Lindsay A.

AU - Finch, Nicole

AU - Graff Radford, Neill R

AU - Head, Elizabeth

AU - Hofree, Matan

AU - Huang, Ruochun

AU - Johns, Hudson

AU - Karydas, Anna

AU - Knopman, David S

AU - Loboda, Andrey

AU - Masliah, Eliezer

AU - Narasimhan, Ramya

AU - Petersen, Ronald Carl

AU - Podtelezhnikov, Alexei

AU - Pradhan, Suraj

AU - Rademakers, Rosa V

AU - Sun, Chung Huan

AU - Younkin, Steven G

AU - Miller, Bruce L.

AU - Ideker, Trey

AU - Wyss-Coray, Tony

PY - 2016/4/26

Y1 - 2016/4/26

N2 - Background: Biological pathways that significantly contribute to sporadic Alzheimer's disease are largely unknown and cannot be observed directly. Cognitive symptoms appear only decades after the molecular disease onset, further complicating analyses. As a consequence, molecular research is often restricted to late-stage post-mortem studies of brain tissue. However, the disease process is expected to trigger numerous cellular signaling pathways and modulate the local and systemic environment, and resulting changes in secreted signaling molecules carry information about otherwise inaccessible pathological processes. Results: To access this information we probed relative levels of close to 600 secreted signaling proteins from patients' blood samples using antibody microarrays and mapped disease-specific molecular networks. Using these networks as seeds we then employed independent genome and transcriptome data sets to corroborate potential pathogenic pathways. Conclusions: We identified Growth-Differentiation Factor (GDF) signaling as a novel Alzheimer's disease-relevant pathway supported by in vivo and in vitro follow-up experiments, demonstrating the existence of a highly informative link between cellular pathology and changes in circulatory signaling proteins.

AB - Background: Biological pathways that significantly contribute to sporadic Alzheimer's disease are largely unknown and cannot be observed directly. Cognitive symptoms appear only decades after the molecular disease onset, further complicating analyses. As a consequence, molecular research is often restricted to late-stage post-mortem studies of brain tissue. However, the disease process is expected to trigger numerous cellular signaling pathways and modulate the local and systemic environment, and resulting changes in secreted signaling molecules carry information about otherwise inaccessible pathological processes. Results: To access this information we probed relative levels of close to 600 secreted signaling proteins from patients' blood samples using antibody microarrays and mapped disease-specific molecular networks. Using these networks as seeds we then employed independent genome and transcriptome data sets to corroborate potential pathogenic pathways. Conclusions: We identified Growth-Differentiation Factor (GDF) signaling as a novel Alzheimer's disease-relevant pathway supported by in vivo and in vitro follow-up experiments, demonstrating the existence of a highly informative link between cellular pathology and changes in circulatory signaling proteins.

UR - http://www.scopus.com/inward/record.url?scp=84969256193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969256193&partnerID=8YFLogxK

U2 - 10.1186/s13024-016-0095-2

DO - 10.1186/s13024-016-0095-2

M3 - Article

C2 - 27112350

AN - SCOPUS:84969256193

VL - 11

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 31

ER -